TY - JOUR
T1 - Coronavirus Disease-19
T2 - An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid)
AU - Abu-Raya, Bahaa
AU - Migliori, Giovanni Battista
AU - O'Ryan, Miguel
AU - Edwards, Kathryn
AU - Torres, Antoni
AU - Alffenaar, Jan-Willem
AU - Märtson, Anne-Grete
AU - Centis, Rosella
AU - D'Ambrosio, Lia
AU - Flanagan, Katie
AU - Hung, Ivan
AU - Lauretani, Fulvio
AU - Leung, Chi Chi
AU - Leuridan, Elke
AU - Maertens, Kirsten
AU - Maggio, Marcello Giuseppe
AU - Nadel, Simon
AU - Hens, Niel
AU - Niesters, Hubert
AU - Osterhaus, Albert
AU - Pontali, Emanuele
AU - Principi, Nicola
AU - Rossato Silva, Denise
AU - Omer, Saad
AU - Spanevello, Antonio
AU - Sverzellati, Nicola
AU - Tan, Tina
AU - Torres-Torreti, Juan Pablo
AU - Visca, Dina
AU - Esposito, Susanna
N1 - Copyright © 2020 Abu-Raya, Migliori, O'Ryan, Edwards, Torres, Alffenaar, Märtson, Centis, D'Ambrosio, Flanagan, Hung, Lauretani, Leung, Leuridan, Maertens, Maggio, Nadel, Hens, Niesters, Osterhaus, Pontali, Principi, Rossato Silva, Omer, Spanevello, Sverzellati, Tan, Torres-Torreti, Visca and Esposito.
PY - 2020
Y1 - 2020
N2 - Coronavirus disease 2019 (COVID-19) is a rapidly evolving, highly transmissible, and potentially lethal pandemic caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of June 11 2020, more than 7,000,000 COVID-19 cases have been reported worldwide, and more than 400,000 patients have died, affecting at least 188 countries. While literature on the disease is rapidly accumulating, an integrated, multinational perspective on clinical manifestations, immunological effects, diagnosis, prevention, and treatment of COVID-19 can be of global benefit. We aimed to synthesize the most relevant literature and experiences in different parts of the world through our global consortium of experts to provide a consensus-based document at this early stage of the pandemic.
AB - Coronavirus disease 2019 (COVID-19) is a rapidly evolving, highly transmissible, and potentially lethal pandemic caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of June 11 2020, more than 7,000,000 COVID-19 cases have been reported worldwide, and more than 400,000 patients have died, affecting at least 188 countries. While literature on the disease is rapidly accumulating, an integrated, multinational perspective on clinical manifestations, immunological effects, diagnosis, prevention, and treatment of COVID-19 can be of global benefit. We aimed to synthesize the most relevant literature and experiences in different parts of the world through our global consortium of experts to provide a consensus-based document at this early stage of the pandemic.
U2 - 10.3389/fmed.2020.572485
DO - 10.3389/fmed.2020.572485
M3 - Review article
C2 - 33195319
VL - 7
SP - 572485
JO - Frontiers in Medicine
JF - Frontiers in Medicine
SN - 2296-858X
ER -